食道癌患者的生存期与个性特征、应付方式及免疫功能的相关性研究

Study of survival time related to personality coping style and immunity function in the patients with esophagus cancer

目的探讨食道癌患者的生存期与个性特征、应付方式等心理因素及其与免疫功能的关系。方法对食道癌晚期患者(食道癌Ⅰ组)、食道癌较长生存期患者(食道癌Ⅱ组)及正常健康人(对照组)分别进行明尼苏达多相个性测验(MMPI)、应付方式问卷(CSQ)、免疫功能测试,并做相关分析。结果(1)MMPI:食道癌Ⅱ组人格障碍评分(42.0±10.5),社会内向评分(42.2±11.6),低于其他两组犤食道癌Ⅰ组为(49.3±11.2)分和(48.3±9.4)分,对照组为(48.6±10.9)分和(39.9±11.5)分犦;P均<0.05。(2)CSQ:解决问题和求助因子分,食道癌Ⅰ组犤分别为(0.68±0.27)分和(0.42±0.18)分犦均低于食道癌Ⅱ组犤分别为(0.82±0.18)分和(0.65±0.21)分犦,P<0.05和P<0.01。食道癌Ⅱ组更多采用成熟的应对方式。(3)自然杀伤细胞(NK细胞):食道癌Ⅱ组水平(21.4±9.2)高于食道癌Ⅰ组犤(14.2±8.8)犦P<0.05;而NK细胞水平与MMPI的抑郁(r=-0.35)、人格障碍((r=-0.39)、偏执(r=-0.29)、精神衰弱(r=-0.30)及精神分裂(r=-0.30)等量表呈负相关,与CSQ的解决问题因子(r=0.35)及应付方式类型(r=0.34)呈正相关。结论与食道癌Ⅰ组比较,食道癌Ⅱ组更为外向,负性情绪更少,更多采用成熟的应对方式,其NK细胞水平较高,对食道癌的预后产生了积极的影响。

Objective:To study the mechanism in which the personality coping style influenced survival time by changing immunity function in the patients with esophagus cancer.Methods:The Minnesota Multiphase Personality Inventory(MMPI),coping style questionaires(CSQ)and immunity function were measured in the patients with esophagus cancer on late stage(group Ⅰ),esophagus cancer patients with longer survival time(groupⅡ),and normal control.Results:Psychopathic deviate,social introversion subscale scores of MMPI in group Ⅱ were significantly lower than that in the other two groups(P < 0 5).Statistical difference were found between group I and group Ⅱ in problem-saving factor(SP) and help-seeking factor of CSQ(P < 0 05). Natural killer cell(NKC)level in group Ⅱ was significantly higher than in group I(P < 0.05).There was negative correlation between the NKC and depression,psychopathic deviate,paranoia,psychasthenia,schizophrenia subscale scores of MMPI,there was positive correlation betwwen NKC and SP,coping type in patients with esophagus cancer.Conclusion:The esophagus cancer patients with longer survival time are more extroversive and have more mature coping styles.Their NKC level is relatively higher.The results may be advantageous to improve the prognosis of esophagus cancer.